Tacrolimus
Tacrolimus, a macrolide lactone isolated from Streptomyces tsukubaensis, is a potent immunosuppressant. Structurally, it is similar to sirolimus and everolimus, consisting of a 23-member carbon ring and a hemiketal-masked α,β-diketoamide function. Inside cells, it binds a family of binding proteins called FKBP, and then forms a pentameric complex comprising tacrolimus, FKBP, calcineurins A and B, and calmodulin. This complex inhibits the phosphatase activity of calcineurin, which is required to activate transcriptional factors for the transport into cell nucleus. As a result, the gene expression of T-lymphocytes is impaired, resulting in suppressed synthesis of cytokines and inflammatory mediators, thus exerting immunosuppressive effects. Therefore, tacrolimus is widely used to prevent graft-versus-host interaction in solid organ transplant, including allogeneic liver transplantation, kidney transplantation, pancreatic islet transplantation, and atopic dermatitis.
Tacrolimus is extensively metabolized by the cytochrome P450 system, mainly CYP3A4. Therefore, drugs that inhibit CYP3A4, for example, calcium channel blockers, antifungal agents, some antibiotics, grapefruit and the drugs that induce CYP3A4, for example, anticonvulsants, and rifampin, can affect the concentration of tacrolimus. Peak concentration in the blood is observed at 0.5 to 4 hours after administration. About 90% of tacrolimus is distributed inside the cellular component of blood. Therefore, whole blood is the preferred specimen for the analysis of trough concentration. Approximately, 99% of tacrolimus in the plasma is bound with proteins, primarily α1-acid glycoprotein, lipoproteins, albumin, and globulins. The fecal excretion of the metabolites is the major route of elimination with the average half-life of 8 to 12 hours. Excessive accumulation of its metabolites due to impaired bile clearance as seen in liver transplantation patients with hyperbilirubinemia may result in significant high bias in the immunoassay results.
The optimal therapeutic target is to keep the blood level between 5.0 to 15.0 ng/mL. Higher levels are preferred immediately after the transplant, but because the organ function stabilizes at about 4 weeks after transplant, dose is generally reduced below trough concentration of 20 ng/mL. Higher doses are associated with toxicity and opportunistic infections, and lower levels can lead to organ rejection. Therefore, it is crucial to monitor the blood level of tacrolimus during therapy.
- As an aid in the management of kidney, liver, and heart transplant patients receiving tacrolimus therapy
- Monitoring whole blood tacrolimus concentration during therapy, particularly in individuals co-administered CYP3A4 substrates, inhibitors, or inducers
- Optimize drug therapy and monitor patient adherence
- Most individuals display optimal response to tacrolimus with trough whole blood levels of 5.0 to 15.0 ng/mL.
- Preferred therapeutic ranges may vary by transplant type, protocol, and comedications
5.0-15.0 ng/mL (Trough)
Toxic value: > 25 ng/mL
Whole blood (EDTA), Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Drugs. 2003;63(12):1247-97. [PMID: 12790696]
- Clin Ther. 2002;24(3):330-50[PMID: 11952020]
- Clin Pharmacokinet. 2002;41(11):813-51. [PMID: 12190331]
- J Clin Pharmacol. 2001;41(5):542-51. [PMID: 11361051]
- Clin Chem. 1996;42(9):1426-32. [PMID: 8787699]
- Clin Pharmacokinet. 1995;29(6):404-30. [PMID: 8787947]
- Snozek CLH, McMillin GA, Moyer TP. “Therapeutic drugs and their management.” Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed. 2012. Page 1057-1108.